Vertex Pharmaceuticals (VRTX) down following data

Vertex Pharmaceuticals Incorporated VRTX shares declined 3.6% to $126.25 after the company reported data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor. Share volume was three million, compared to an all-day average of 1.6 million